Based on the Kiniksa Pharmaceuticals Ltd stock forecast from 3 analysts, the average analyst target price for Kiniksa Pharmaceuticals Ltd is USD 35.75 over the next 12 months. Kiniksa Pharmaceuticals Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Kiniksa Pharmaceuticals Ltd is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Kiniksa Pharmaceuticals Ltd’s stock price was USD 20.28. Kiniksa Pharmaceuticals Ltd’s stock price has changed by -8.69% over the past week, -5.72% over the past month and +14.71% over the last year.
No recent analyst target price found for Kiniksa Pharmaceuticals Ltd
No recent average analyst rating found for Kiniksa Pharmaceuticals Ltd
Company Overview Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom. Read Less
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin...Read More
Frequently Asked Questions About Kiniksa Pharmaceuticals Ltd (KNSA) Stock
Based on ratings from 3 analysts Kiniksa Pharmaceuticals Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on KNSA's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for KNSA is USD 35.75 over the next 12 months. The maximum analyst target price is USD 40 while the minimum anlayst target price is USD 34.
KNSA stock's Price/Earning ratio is 163.15.
Our analysis grades KNSA stock's Price / Earning ratio at F. This means that KNSA stock's Price/Earning ratio is above 91% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this KNSA may be a overvalued for its sector.
The last closing price of KNSA's stock was USD 20.28.
The most recent market capitalization for KNSA is USD 1.56B.
Based on targets from 3 analysts, the average taret price for KNSA is projected at USD 35.75 over the next 12 months.
This means that KNSA's stock price may go up by +83.52% over the next 12 months.
We can't find any ETFs which contains Kiniksa Pharmaceuticals Ltd's stock.
As per our most recent records Kiniksa Pharmaceuticals Ltd has 315 Employees.
Kiniksa Pharmaceuticals Ltd's registered address is 23 Old Bond Street, London, United Kingdom, WIS 4PZ.
You can get more information about it from Kiniksa Pharmaceuticals Ltd's website at https://www.kiniksa.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Kiniksa Pharmaceuticals Ltd (KNSA) Stock
Based on ratings from 3 analysts Kiniksa Pharmaceuticals Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on KNSA's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for KNSA is USD 35.75 over the next 12 months. The maximum analyst target price is USD 40 while the minimum anlayst target price is USD 34.
KNSA stock's Price/Earning ratio is 163.15.
Our analysis grades KNSA stock's Price / Earning ratio at F. This means that KNSA stock's Price/Earning ratio is above 91% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this KNSA may be a overvalued for its sector.
The last closing price of KNSA's stock was USD 20.28.
The most recent market capitalization for KNSA is USD 1.56B.
Based on targets from 3 analysts, the average taret price for KNSA is projected at USD 35.75 over the next 12 months.
This means that KNSA's stock price may go up by +83.52% over the next 12 months.
We can't find any ETFs which contains Kiniksa Pharmaceuticals Ltd's stock.
As per our most recent records Kiniksa Pharmaceuticals Ltd has 315 Employees.
Kiniksa Pharmaceuticals Ltd's registered address is 23 Old Bond Street, London, United Kingdom, WIS 4PZ.
You can get more information about it from Kiniksa Pharmaceuticals Ltd's website at https://www.kiniksa.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for KNSA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
